This is a non-core endpoint: only basic statistics are computed.
Benign neoplasm: Retina
CD2_BENIGN_RETINA_EXALLC
No definition available.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
|
1. Apply sex-specific ruleNone |
- |
2. Check conditionsNone |
|
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
- |
4. Check minimum number of eventsNone |
- |
5. Include endpointsNone |
- |
6. Filter based on genotype QC (FinnGen only)None |
- |
Control definitions (FinnGen only)
- Control exclude
- C3_CANCER, C3_CANCER_WIDE
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- D31
- Name in latin
- Neoplasma benignum retinae
Similar endpoints
↥List of similar endpoints to
Benign neoplasm: Retina
based on the number of shared cases.
Similar with more cases:
- Benign neoplasm: Retina
- Benign neoplasm of eye and adnexa
- Benign neoplasm of eye and adnexa
- Benign neoplasms
- Benign neoplasms
Similar with less cases:
Case counts by codes
↥FinnGen case counts by registry codes:
No upset plot: script not run.
No upset table: script not run.
Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 191 | 111 | 80 |
| Unadjusted period prevalence (%) | 0.04 | 0.04 | 0.04 |
| Median age at first event (years) | 57.72 | 52.66 | 64.74 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 165
- Matched controls
- 1649
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
D31.2
ICD-10 Finland
Benign neoplasm: Retina
+∞
232.4
163
*
D31.3
ICD-10 Finland
Benign neoplasm: Choroid
95.8
40.2
43
6
XCK10
NOMESCO Finland
Photography of fundus of eye
11.0
29.0
60
81
CK2L4
NOMESCO Finland
Wide-field/panoramic imaging of ocular fundus
238.6
21.1
21
*
CK2S4
NOMESCO Finland
Plain photography of ocular fundus
14.0
20.7
36
32
XCD10
NOMESCO Finland
Electrophysiological examination of eye
22.7
18.9
27
14
Z01.0
ICD-10 Finland
Examination of eyes and vision
4.5
13.8
55
163
CK2X4
NOMESCO Finland
Optical coherence tomography (OCT) of ocular fundus
5.9
11.5
33
67
XCW99
NOMESCO Finland
Other investigative procedure of eye
4.9
11.4
39
97
CKC20
NOMESCO Finland
Cryopexy of undetached retina
105.7
9.5
10
*
C44.31
ICD-10 Finland
Basocellular carcinoma of the skin on another or unspecified part of the face
105.7
9.5
10
*
8090/3-C44.9
ICD-O-3
Basal cell carcinoma, NOS, of skin, NOS
+∞
9.5
9
*
115
Kela drug reimbursment
Breast cancer
+∞
9.5
9
*
130
Kela drug reimbursment
Malignant tumour
+∞
9.5
9
*
QAE10
NOMESCO Finland
Excision of other lesion extending through all layers of skin in head or neck
8.4
8.9
19
25
H02AB02
ATC
dexamethasone; systemic
52.8
8.8
10
*
WX140
NOMESCO Finland
Parabulbar anesthesy
9.3
8.5
17
20
C61
ICD-10 Finland
Malignant neoplasm of prostate
94.6
8.5
9
*
8140/3-C61.9
ICD-O-3
Adenocarcinoma, NOS, of prostate gland
+∞
8.4
8
*
A04AA02
ATC
granisetron; systemic, transdermal
+∞
8.4
8
*
C50.99
ICD-10 Finland
Breast, unspecified
+∞
7.3
7
*
XCD20
NOMESCO Finland
Photoangiography of eye
9.4
7.2
14
16
HAB40
NOMESCO Finland
Wedge excision of mammary gland
72.4
6.5
7
*
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
4.9
6.4
20
45
WD105
NOMESCO Finland
Cystostatic therapy of methastized malignancy
+∞
6.3
6
*
116
Kela drug reimbursment
Prostate cancer
+∞
6.3
6
*
PJA12
NOMESCO Finland
Sentinel node biopsy
+∞
6.3
6
*
D22.3
ICD-10 Finland
Melanocytic naevi of other and unspecified parts of face
13.2
6.2
10
8
A03FA01
ATC
metoclopramide; systemic, rectal
3.2
6.0
31
110
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
109
691
2.34
7.65
7.5
3.2
13.0
11.4
umol/l
0.54
109
644
37
181
2.30
4.48
1.7
1.9
—
—
—
0
0
8
9
9.21
4.32
1.0
1.6
—
—
—
0
0
85
587
1.81
3.86
6.8
4.1
1.2
1.2
mmol/l
0.06
79
523
92
662
1.75
3.55
8.2
4.6
1.2
1.2
mmol/l
0.21
73
567
27
130
2.25
3.38
2.7
1.9
4.8
6.1
umol/l
0.81
22
108
58
381
1.75
2.99
3.5
2.8
0.1
0.5
e6/l
3.27
45
273
8
17
4.86
2.95
1.0
1.2
—
—
—
0
0
108
843
1.65
2.88
4.5
3.5
7.0
6.6
mmol/l
0.63
103
768
82
599
1.65
2.83
2.4
2.2
76.7
76.8
nmol/l
0.01
76
536
82
603
1.63
2.73
4.0
3.5
—
—
—
0
0
12
43
2.91
2.70
1.6
1.7
—
—
—
0
0
12
44
2.84
2.60
1.6
1.8
—
—
—
0
0
33
192
1.87
2.51
20.9
22.3
1.3
1.3
inr
—
5
29
15
64
2.46
2.46
1.3
1.8
—
—
—
0
0
67
479
1.61
2.45
3.9
2.9
—
—
—
0
0
63
444
1.63
2.44
2.8
3.1
1172.5
1414.6
ng/l
0.17
55
367
92
711
1.57
2.41
3.5
3.6
0.0
0.0
estimate
0.00
18
126
21
106
2.10
2.36
1.1
1.2
59.2
145.7
iu/ml
—
5
46
16
73
2.30
2.28
3.6
3.5
24.9
25.2
mmol/l
0.09
16
73
91
714
1.52
2.16
5.0
5.0
0.0
0.0
estimate
0.00
21
122
160
1429
1.74
2.11
6.0
4.5
2.0
2.7
mu/l
0.38
149
1305
23
127
1.92
2.05
1.5
1.9
—
—
—
0
0
84
656
1.50
2.00
2.6
2.7
122.8
104.9
ug/l
0.23
78
606
23
128
1.91
2.00
1.5
1.8
—
—
—
0
0
91
727
1.48
1.92
3.5
3.5
0.0
0.0
estimate
0.00
20
117
62
458
1.52
1.91
2.8
1.9
59.7
57.4
u/l
0.20
62
420
14
66
2.21
1.87
6.7
4.1
1.0
1.6
%
1.67
14
66
135
1171
1.52
1.87
5.0
3.8
14.7
14.8
pmol/l
0.22
125
1067
17
87
2.05
1.86
1.5
1.4
—
—
—
0
0
97
795
1.45
1.74
10.9
5.6
4.1
4.1
e9/l
0.06
88
696
22
127
1.83
1.73
5.4
4.3
0.4
1.4
mmol/l
0.51
17
99
8
31
2.65
1.68
1.9
1.5
—
—
—
0
0
72
564
1.44
1.62
3.6
3.7
—
—
—
0
0
7
26
2.75
1.59
1.3
1.4
—
—
—
0
0
13
64
2.11
1.58
7.5
4.2
0.8
0.7
%
0.47
13
64
34
229
1.59
1.56
2.6
2.5
1.0
1.1
e6/l
0.02
18
122
74
589
1.42
1.51
4.0
4.0
35.0
103.6
ng/l
0.59
51
409
31
206
1.60
1.50
3.3
2.8
3.3
2.6
e6/l
0.19
16
100
50
370
1.48
1.50
3.8
3.7
0.0
0.0
estimate
0.00
19
120
7
28
2.56
1.46
1.4
1.3
224.0
64.2
pmol/l
—
7
28
78
633
1.39
1.41
2.0
1.8
98.1
96.0
pmol/l
0.14
39
322
29
193
1.59
1.40
1.5
1.7
29.0
29.4
s
0.14
29
186
165
1527
1.59
1.39
16.8
11.3
21.1
21.2
mg/l
0.01
130
1154
5
17
2.99
1.36
1.0
1.1
—
—
—
0
0
47
350
1.45
1.36
3.9
3.4
22.0
25.0
%
0.92
23
163
130
1153
1.40
1.34
4.0
3.9
12.5
11.4
mm/h
0.34
124
1054
38
273
1.49
1.31
3.9
3.9
353.9
94.6
ng/l
0.59
32
207
172
1615
1.65
1.27
20.8
13.2
78.4
77.8
umol/l
0.11
172
1615
52
400
1.41
1.26
1.7
1.6
1.3
1.4
mmol/l
0.20
42
341
39
286
1.46
1.22
2.1
1.8
—
—
—
0
0
10
50
2.06
1.19
1.9
1.6
474.2
334.1
ug/l
—
10
43
5
20
2.54
1.16
1.2
1.2
—
—
—
0
0
7
33
2.16
1.06
2.9
3.2
—
—
—
0
0
42
322
1.39
1.04
1.7
1.7
491.6
14440876.1
pmol/l
0.50
37
277
13
77
1.74
0.98
1.0
1.0
—
—
—
0
0
172
1633
1.54
0.97
13.3
8.2
27.7
25.1
u/l
1.34
167
1567
6
30
2.03
0.87
1.8
1.7
—
—
—
0
0
20
139
1.49
0.83
3.9
3.0
—
—
—
0
0
18
123
1.51
0.81
7.4
1.6
52.2
68.0
ml/min/173m2
1.09
11
45
0
26
0.00
0.79
0.0
1.2
—
4.9
—
0
12
0
26
0.00
0.79
0.0
1.0
—
—
—
0
0
43
349
1.30
0.74
2.5
2.1
2.6
3.0
mg/l
0.62
38
298
5
25
2.03
0.73
1.0
2.1
3.6
3.5
g/l
—
5
25
54
454
1.26
0.71
4.8
3.8
2.3
2.0
ug/l
0.44
48
410
5
30
1.68
0.62
1.4
1.2
—
—
—
0
0
5
30
1.68
0.62
1.0
1.3
—
—
—
0
0
32
257
1.29
0.60
1.3
1.4
—
—
—
0
0
0
22
0.00
0.59
0.0
1.7
—
—
—
0
0
0
22
0.00
0.59
0.0
1.2
—
1.2
—
0
10
6
40
1.52
0.52
2.0
1.7
—
—
—
0
0
146
1390
1.21
0.50
16.0
11.9
40.6
40.3
%
0.13
95
1009
35
292
1.24
0.50
1.7
1.7
1385.7
1255.4
nmol/l
0.35
29
230
159
1528
1.24
0.49
5.2
4.4
6.0
5.9
mmol/l
0.24
146
1402
18
138
1.34
0.47
3.6
2.4
267.0
242.0
u/l
0.69
18
133
7
48
1.48
0.47
1.1
1.1
—
—
—
0
0
7
48
1.48
0.47
1.1
1.1
—
—
—
0
0
38
327
1.20
0.41
1.4
1.3
0.5
1.5
u/ml
—
8
103
0
15
0.00
0.41
0.0
4.7
—
—
—
0
0
0
15
0.00
0.41
0.0
1.4
—
—
—
0
0
0
16
0.00
0.41
0.0
1.9
—
—
—
0
0
0
16
0.00
0.41
0.0
1.4
—
—
—
0
0
0
18
0.00
0.40
0.0
1.2
—
—
—
0
0
0
18
0.00
0.40
0.0
1.1
—
—
—
0
0
9
66
1.38
0.39
1.9
3.5
24.0
25.2
mmol/l
—
9
56
11
82
1.36
0.35
1.6
1.5
—
—
—
0
0
29
250
1.19
0.32
2.9
2.5
0.7
0.7
ug/l
0.02
20
166
7
54
1.31
0.31
1.0
1.1
9.8
10.2
g/l
—
7
49
11
84
1.33
0.30
1.3
1.3
—
—
—
0
0
153
1485
1.15
0.29
4.4
4.0
1.4
1.3
mmol/l
0.75
139
1371
15
181
0.81
0.26
10.2
7.3
—
—
—
0
0
5
75
0.66
0.26
2.2
1.9
—
—
—
0
0
13
158
0.81
0.24
1.8
1.8
—
—
—
0
0
161
1575
1.14
0.23
5.7
5.0
2.8
2.7
mmol/l
0.06
143
1464
0
10
0.00
0.21
0.0
1.4
—
—
—
0
0
0
10
0.00
0.21
0.0
1.6
—
—
—
0
0
0
12
0.00
0.21
0.0
1.0
—
—
—
0
0
0
12
0.00
0.21
0.0
1.0
—
45.4
—
0
7
0
12
0.00
0.21
0.0
1.0
—
526.6
—
0
7
5
43
1.17
0.21
2.6
1.7
16.4
1.3
ug/l
—
5
37
0
13
0.00
0.21
0.0
1.0
—
—
—
0
0
0
13
0.00
0.21
0.0
1.5
—
—
—
0
0
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
0
13
0.00
0.21
0.0
1.5
—
—
—
0
0
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
0
14
0.00
0.20
0.0
1.1
—
—
—
0
0
0
14
0.00
0.20
0.0
1.1
—
—
—
0
0
0
14
0.00
0.20
0.0
1.1
—
—
—
0
0
13
109
1.21
0.19
2.9
2.9
5.3
4.2
kpa
0.74
13
102
7
59
1.19
0.18
1.0
1.1
—
—
—
0
0
148
1449
1.10
0.17
17.8
10.1
78.7
79.9
ml/min/173m2
0.25
124
1155
24
266
0.89
0.17
1.1
1.3
28.8
13.1
u/ml
—
8
97
6
75
0.79
0.16
2.2
2.2
1.1
1.2
%
—
6
75
146
1432
1.08
0.14
6.5
5.9
40.9
40.0
mmol/mol
0.54
136
1343
99
965
1.05
0.10
3.1
3.0
—
—
—
0
0
11
96
1.15
0.10
3.1
3.0
5.2
5.0
kpa
0.23
11
85
6
57
1.05
0.08
1.0
1.1
3.1
3.1
g/l
—
6
48
156
1545
1.05
0.06
5.1
4.5
4.6
4.6
mmol/l
0.00
143
1448
155
1540
1.03
0.03
5.2
4.4
1.4
1.5
mmol/l
2.08
140
1435
27
264
1.03
0.00
1.5
1.5
—
—
—
0
0
14
141
0.99
0.00
1.9
2.0
—
—
—
0
0
11
107
1.03
0.00
2.3
1.3
66.1
67.5
g/l
0.29
11
99
15
153
0.98
0.00
1.9
2.1
—
—
—
0
0
28
277
1.01
0.00
1.3
1.3
36.8
43.0
iu/ml
—
9
98
19
195
0.97
0.00
4.7
4.7
31.2
30.9
%
0.03
13
133
5
58
0.86
0.00
1.2
2.0
—
144.0
—
0
5
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
0.00
0.0
1.6
—
—
—
0
0
5
58
0.86
0.00
1.4
1.5
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
5
51
0.98
0.00
1.0
1.1
38.7
38.3
g/l
—
5
44
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
6
61
0.98
0.00
2.2
1.8
—
—
—
0
0
0
9
0.00
0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
2.7
—
823.0
—
0
6
0
9
0.00
0.00
0.0
1.4
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: CD2_BENIGN_RETINA_EXALLC – Benign neoplasm: Retina
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).